Abstract

cfDNA Analysis in ALK-positive NSCLC Patients and Potential Clinical Utility

Jean-francois Martini, Sr. Director, Translational Oncology, Immuno-Oncology, Early Development, Pfizer

Lorlatinib exhibited antitumor activity across a variety of ALK kinase domain resistance mutations, including the difficult-to-treat ALK G1202R mutation. Responses to lorlatinib were also seen in patients resistant to prior ALK TKIs and without detectable ALK resistance mutations in plasma.